Pelin Teke Kısa

Pelin Teke Kısa

Auto-generated profile, based on publicly available information

Pelin Teke Kısa

Division of Pediatric Metabolism and Nutrition, Department of Pediatrics Dokuz Eylul University Faculty of Medicine İzmir Türkiye

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2021 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
PKPelin Teke Kısa
Pelin Teke Kısa
GYGonca Kılıç Yıldırım
Gonca Kılıç Yıldırım
BHBurcu Ozturk Hismi
Burcu Ozturk Hismi
SYSevil Yıldız
Sevil Yıldız
ÖKÖzge Küsbeci
Özge Küsbeci
NANur Arslan
Nur Arslan

1 May 2021 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
PKPelin Teke Kisa
Pelin Teke Kisa
MGMehmet Gunduz
Mehmet Gunduz
SDSevil Dorum
Sevil Dorum
OUOzlem Unal Uzun
Ozlem Unal Uzun
NCNafiye Emel Cakar
Nafiye Emel Cakar
NANur Arslan
Nur Arslan

4 November 2021 in Annals of Nutrition and Metabolism
Verified
Journal Article
Closed access
PDF file
PKPelin Teke Kisa
Pelin Teke Kisa
SESemra Eroglu Erkmen
Semra Eroglu Erkmen
HBHilal Bahceci
Hilal Bahceci
ZGZumrut Arslan Gulten
Zumrut Arslan Gulten
AAAyca Aydogan
Ayca Aydogan
NANur Arslan
Nur Arslan
Introduction: Nitisinone used in alkaptonuria (AKU) can result in keratopathy due to strongly increased tyrosine levels. Methods: This study aimed to investigate nutritional status and changes in plasma tyrosine and phenylalanine and urinary homogentisic acid (u-HGA) levels in 8 adult AKU patients (mean age, 56.3 ± 4.7 years) who were on tyrosine/phenylalanine-restricted diet together with 2 mg/day nitisinone. Results: The treatment period was 23.4 ± 6.9 months. Daily dietary protein intake was restricted to 0.8–1.0 g/kg/day. Daily tyrosine intake was restricted to 260–450 mg/day for females and 330–550 mg/day for males. Tyrosine/phenylalanine-free amino acid supplements accounted for an average of 56.1% of daily protein intake. The following assessments were performed: anthropometric and plasma tyrosine level measurements every 2 months; ophthalmological examination every 6 months, and nutritional laboratory analyses and measurements of plasma amino acids and u-HGA once in a year. It was targeted to keep the plasma tyrosine level <500 μmol/L. The plasma tyrosine level was 700 μmol/L was detected. The u-HGA level before and after the 1st year of treatment was 1,429.3 ± 1,073.4 mmol/mol creatinine and 33.6 ± 9.5 mmol/mol creatinine, respectively. None of the patients developed keratopathy or experienced weight loss and protein or micronutrient deficiency. Conclusion: AKU patients should receive tyrosine/phenylalanine-restricted diet for reducing plasma tyrosine level to the safe range. Tyrosine/phenylalanine-free amino acid supplements can be safely used to enhance dietary compliance. Keratopathy and nutrient deficiency should be frequently monitored.

15 December 2020 in Journal of Pediatric Endocrinology and Metabolism
Verified
Journal Article
Closed access
PDF file
PKPelin Teke Kisa
Pelin Teke Kisa
NANur Arslan
Nur Arslan
Inborn errors of metabolism consist of a heterogeneous group of disorders with various organ systems manifestations, and some metabolic diseases also cause immunological disorders or dysregulation. In this review, metabolic diseases that affect the immunological system and particularly lead to primary immune deficiency will be reviewed. In a patient with frequent infections and immunodeficiency, the presence of symptoms such as growth retardation, abnormal facial appearance, heart, skeletal, lung deformities, skin findings, arthritis, motor developmental retardation, seizure, deafness, hepatomegaly, splenomegaly, impairment of liver function tests, the presence of anemia, thrombocytopenia and eosinophilia in hematological examinations should suggest metabolic diseases for the underlying cause. In some patients, these phenotypic findings may appear before the immunodeficiency picture. Metabolic diseases leading to immunological disorders are likely to be rare but probably underdiagnosed. Therefore, the presence of recurrent infections or autoimmune findings in a patient with a suspected metabolic disease should suggest that immune deficiency may also accompany the picture, and diagnostic examinations in this regard should be deepened.

15 June 2017 in The Journal of Pediatric Research
Verified
Journal Article
Closed access
PKPelin Teke Kısa
Pelin Teke Kısa
EKEngin Köse
Engin Köse
MAMerve Ateşoğlu
Merve Ateşoğlu
NANur Arslan
Nur Arslan
Aim: Mucopolysaccharidoses (MPSs) are a group of lysosomal storage disorders caused by the deficiency of spesific lysosomal enzymes required to break down glycosaminoglycans. MPSs should be suspected in a child with coarse facial features, organomegaly, and bone disease (dysostosis multiplex), with central nervous system abnormalities. Early diagnosis and treatment can improve outcomes in MPS. The aim of this study was to evaluate the demographic characteristics and clinical findings of our MPS patients.\ud Materials and Methods: This is a retrospective study which included 27 MPS patients who were diagnosed and treated in our center.\ud Results: The mean age of the group was 112.3±52.5 months (36-196 months); the mean onset age of symptoms was 40.8±30.6 months (4-112 months), and the mean time from symptom onset to diagnosis was 16.3±21.4 months (0-80 months). MPS subgroups were Type III in 13 (48%) patients, Type II in seven (26%), Type VI in four (15%), Type I in two (7%) patients and Type IV in one patient. Nine (33.3%) patients received enzyme replacement therapy (ERT). The mean duration of ERT was 31.3±21.5 months (9-67 months).\ud Conclusion: MPS Type III was found to be the most common subgroup in our center. We can speculate that the mean time from symptom onset to diagnosis was found too long for MPS in which early diagnosis improves the prognosis. Increasing awareness of the disease in physicians encountering these patients in different clinics will be an important factor in the early diagnosis of the disease

1 January 2020 in Turkish Archives of Pediatrics
Verified
Journal Article
Open access
PKPelin Teke Kısa
Pelin Teke Kısa
SESuna Emir
Suna Emir
As the survival rates in children with cancer reach up to 80%, this improvement in survival increases the number of patients under follow-up. After cancer treatment is completed, patients are taken to follow-up surveillance to ensure the early detection of recurrence and the late effects of treatments. The frequency and necessity of surveillance screening tests are controversial. This study aimed to assess the efficacy of surveillance screening in the detection of recurrence. The files of 533 children who were diagnosed as having cancer at our pediatric oncology clinic between 2004 and 2013 were retrospectively evaluated. We looked at outcomes after recurrence, the timing and pattern of recurrence, the presence of symptoms during recurrence, physical examination findings, tumor marker levels, laboratory findings, and radiologic tests. Of the 63 patients with recurrence, 23 were symptomatic and 40 were asymptomatic at the time of the recurrence. Tumor location and time of the recurrence did not affect the post recurrence survival. The median post-recurrence survival for patients was 13 (range, 1–98) months. The median post-relapse survival was 10 (range, 1–73) months in patients with symptomatic recurrence, and 16 (range, 1–98) months in patients with asymptomatic recurrence. It was determined that patients in whom recurrence was identified with surveillance tests had longer post-relapse survival time. The 5-year survival rate of 23 patients with symptomatic recurrence was 12.2%; this rate was 49.5% in asymptomatic patients (p<0.05). It should be considered that surveillance testing offers the benefit of prolonging post recurrence survival.